Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ceritinib

FDA-approved product (capsule, oral), marketed as Zykadia.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ceritinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anaplastic lymphoma kinase (alk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ceritinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ceritinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies

    NCT02343679 · start 2015-05

    Registered record
    Registry ID
    NCT02343679
    Conditions
    Hematologic Malignancies
    Interventions
    ceritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2015-05
    Completion
    2022-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematologic Malignancies
    Interventionceritinib
    PhasePhase 2
    Registry statusWithdrawn

  • Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

    NCT02299505 · start 2015-04-09

    Registered record
    Registry ID
    NCT02299505
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    ceritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-04-09
    Completion
    2020-03-06
    Enrolment
    306

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    Interventionceritinib
    PhasePhase 1
    Registry statusCompleted

  • A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

    NCT02336451 · start 2015-04-01

    Registered record
    Registry ID
    NCT02336451
    Conditions
    ALK-positive Non-small Cell Lung Cancer
    Interventions
    Ceritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-04-01
    Completion
    2019-02-06
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK-positive Non-small Cell Lung Cancer
    InterventionCeritinib
    PhasePhase 2
    Registry statusCompleted

  • Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

    NCT02587650 · start 2015-03-26

    Registered record
    Registry ID
    NCT02587650
    Conditions
    ALK Fusion Protein Expression; BRAF wt Allele; Invasive Skin Melanoma; MET Fusion Gene Positive; NRAS wt Allele; NTRK1 Fusion Positive; NTRK2 Fusion Positive; NTRK3 Fusion Positive; RET Fusion Positive; ROS1 Fusion Positive; Stage III Cutaneous Melanoma; Stage IIIA Cutaneous Melanoma; Stage IIIB Cutaneous Melanoma; Stage IIIC Cutaneous Melanoma; Stage IV Cutaneous Melanoma
    Interventions
    Capmatinib; Ceritinib; Entrectinib; Laboratory Biomarker Analysis; Regorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-03-26
    Completion
    2018-07-12
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK Fusion Protein Expression; BRAF wt Allele; Invasive Skin Melanoma; MET Fusion Gene Positive +11 more
    InterventionCapmatinib; Ceritinib; Entrectinib; Laboratory Biomarker Analysis +1 more
    PhasePhase 2
    Registry statusTerminated

  • A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma

    NCT02374489 · start 2015-03

    Registered record
    Registry ID
    NCT02374489
    Conditions
    Cholangiocarcinoma
    Interventions
    LDK378
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-03
    Completion
    2018-01
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholangiocarcinoma
    InterventionLDK378
    PhasePhase 2
    Registry statusTerminated

  • A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

    NCT02276027 · start 2015-01-20

    Registered record
    Registry ID
    NCT02276027
    Conditions
    Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
    Interventions
    BYL719; INC280; LDK378; MEK162
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-01-20
    Completion
    2019-10-15
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
    InterventionBYL719; INC280; LDK378; MEK162
    PhasePhase 2
    Registry statusCompleted

  • Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer

    NCT02227940 · start 2015-01-08

    Registered record
    Registry ID
    NCT02227940
    Conditions
    Advanced Malignant Solid Neoplasm; ALK Positive; Metastatic Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
    Interventions
    Ceritinib; Cisplatin; Gemcitabine Hydrochloride; Laboratory Biomarker Analysis; Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-01-08
    Completion
    2019-02-12
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Malignant Solid Neoplasm; ALK Positive; Metastatic Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer +1 more
    InterventionCeritinib; Cisplatin; Gemcitabine Hydrochloride; Laboratory Biomarker Analysis +2 more
    PhasePhase 1
    Registry statusCompleted

  • Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)

    NCT02186821 · start 2014-09-17

    Registered record
    Registry ID
    NCT02186821
    Conditions
    Tumors With Aberrations in ALK or ROS1
    Interventions
    Ceritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-09-17
    Completion
    2017-12-13
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTumors With Aberrations in ALK or ROS1
    InterventionCeritinib
    PhasePhase 2
    Registry statusTerminated

  • LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

    NCT02040870 · start 2014-03-07

    Registered record
    Registry ID
    NCT02040870
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    LDK378
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2014-03-07
    Completion
    2017-07-27
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionLDK378
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Effect of Hepatic Impairment on LDK378 Pharmacokinetics

    NCT01950481 · start 2014-01

    Registered record
    Registry ID
    NCT01950481
    Conditions
    Normal Hepatic Function; Impaired Hepatic Function
    Interventions
    LDK378
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-01
    Completion
    2016-09
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNormal Hepatic Function; Impaired Hepatic Function
    InterventionLDK378
    PhasePhase 1
    Registry statusCompleted

  • An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

    NCT01964157 · start 2013-09-01

    Registered record
    Registry ID
    NCT01964157
    Conditions
    Non-small Cell Lung Cancer (NSCLC)
    Interventions
    LDK378
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-09-01
    Completion
    2026-01-29
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer (NSCLC)
    InterventionLDK378
    PhasePhase 2
    Registry statusCompleted

  • Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

    NCT01742286 · start 2013-08-28

    Registered record
    Registry ID
    NCT01742286
    Conditions
    ALK-activated Tumors
    Interventions
    Ceritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-08-28
    Completion
    2019-04-26
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK-activated Tumors
    InterventionCeritinib
    PhasePhase 1
    Registry statusCompleted

  • LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

    NCT01828112 · start 2013-06-28

    Registered record
    Registry ID
    NCT01828112
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Ceritinib; Pemetrexed; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-06-28
    Completion
    2023-11-10
    Enrolment
    231

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionCeritinib; Pemetrexed; Docetaxel
    PhasePhase 3
    Registry statusCompleted

  • Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

    NCT01772797 · start 2013-06

    Registered record
    Registry ID
    NCT01772797
    Conditions
    Anaplastic Lymphoma Kinase (ALK); Non-small Cell Lung Cancer
    Interventions
    LDK378; AUY922
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-06
    Completion
    2016-01
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaplastic Lymphoma Kinase (ALK); Non-small Cell Lung Cancer
    InterventionLDK378; AUY922
    PhasePhase 1
    Registry statusCompleted

  • LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

    NCT01685138 · start 2012-12-20

    Registered record
    Registry ID
    NCT01685138
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    LDK378
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-12-20
    Completion
    2018-01-22
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionLDK378
    PhasePhase 2
    Registry statusCompleted